Eicos Sciences, Inc. Report issue

For profit Phase 3
Founded: Palo Alto CA United States (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2019
NCT03867097
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Eicos Sciences, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

iloprost (ventavis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 3)

Raynaud Disease (Phase 3)

Scleroderma, Diffuse (Phase 3)

Scleroderma, Systemic (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1